KoBioLabs, Inc. Logo

KoBioLabs, Inc.

Develops AI-driven microbiome therapeutics for immune, metabolic, and brain disorders.

348150 | KO

Overview

Corporate Details

ISIN(s):
KR7348150004
LEI:
Country:
South Korea
Address:
서울특별시 관악구 관악로 1 220동 745-1호(신림동, 서울대학교종합연구동), 서울특별시
Sector:
Mining and quarrying
Industry:
Mining of non-ferrous metal ores

Description

KoBioLabs, Inc. is a biotechnology company specializing in the development of innovative microbiome therapeutics. The company utilizes its proprietary Smartiome® platform, an AI-driven, multi-omics drug discovery engine using a reverse-translation approach, to identify novel candidates for its pipelines. Its research and development efforts are primarily focused on creating treatments for a range of immune, metabolic, and brain disorders. KoBioLabs employs advanced technologies such as microbe-based drug delivery systems (mDDS) and biofoundry techniques to create a new class of drugs, aiming to address unmet medical needs by modulating biological pathways through microbial interactions.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2025-08-14 00:00
Interim Report
반기보고서 (2025.06)
Korean 1.5 MB
2025-05-15 00:00
Quarterly Report
분기보고서 (2025.03)
Korean 1.1 MB
2025-03-31 00:00
Post-Annual General Meeting Information
정기주주총회결과
Korean 28.2 KB
2025-03-31 00:00
Board/Management Information
사외이사의선임ㆍ해임또는중도퇴임에관한신고
Korean 11.3 KB
2025-03-31 00:00
Board/Management Information
[기재정정]사외이사의선임ㆍ해임또는중도퇴임에관한신고
Korean 14.1 KB
2025-03-20 00:00
Audit Report / Information
사업보고서 (2024.12)
Korean 483.3 KB
2025-03-20 00:00
Audit Report / Information
감사보고서제출
Korean 26.0 KB
2025-03-14 00:00
Pre-Annual General Meeting Information
주주총회소집공고
Korean 225.0 KB
2025-03-06 00:00
Pre-Annual General Meeting Information
주주총회소집결의
Korean 17.6 KB
2025-02-14 00:00
Earnings Release
매출액또는손익구조30%(대규모법인은15%)이상변동
Korean 11.2 KB
2024-12-13 00:00
Pre-Annual General Meeting Information
주주명부폐쇄기간또는기준일설정
Korean 4.3 KB
2024-11-14 00:00
Annual Report
[기재정정]사업보고서 (2023.12)
Korean 1.8 MB
2024-11-14 00:00
Quarterly Report
[기재정정]분기보고서 (2024.03)
Korean 1.1 MB
2024-11-14 00:00
Interim Report
[기재정정]반기보고서 (2024.06)
Korean 1.5 MB
2024-11-14 00:00
Quarterly Report
분기보고서 (2024.09)
Korean 1.2 MB

Automate Your Workflow. Get a real-time feed of all KoBioLabs, Inc. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for KoBioLabs, Inc.

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for KoBioLabs, Inc. via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

iBio, Inc. Logo
AI-powered biotech developing antibody therapeutics for cardiometabolic diseases and obesity.
United States of America
IBIO
Ibotta, Inc. Logo
A performance marketing platform offering cash-back rewards to consumers from CPG brands.
United States of America
IBTA
ICON PLC Logo
Global CRO providing outsourced development & commercialization for pharma, biotech & device firms.
United States of America
ICLR
IDEAYA Biosciences, Inc. Logo
Clinical-stage firm developing precision cancer therapies via synthetic lethality.
United States of America
IDYA
IMGT Corporation Limited Logo
Develops a drug delivery platform using ultrasound and nanotech for oncology.
South Korea
456570
IMMERSION CORP Logo
Licenses patented haptic feedback technology for mobile, gaming, and automotive interfaces.
United States of America
IMMR
IMMUNIC, INC. Logo
Developing oral small molecule therapies for chronic inflammatory and autoimmune diseases.
United States of America
IMUX
IMMUTEP Ltd Logo
Developing LAG-3-based immunotherapies for cancer and autoimmune diseases.
United States of America
IMMP
Operates one of Japan's largest ad networks and a 'Furusato Nozei' tax donation website.
Japan
6535
INBIOGEN CO.,Ltd Logo
Data mining, bioinformatics, and virtual assistance for the life sciences industry.
South Korea
101140

Talk to a Data Expert

Have a question? We'll get back to you promptly.